Regorafenib, which was first approved by the FDA in September 2012, is an oral multi-kinase inhibitor developed by Bayer that targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib was officially launched in China in June 2017 for the treatment of patients with metastatic colorectal cancer (mCRC) who have previously received standard treatment. New application of it is also under research according to the public information [ClinicalTrials.gov Identifier: NCT03793361(Study ID Numbers EREMISS)
Colorectal cancer (CRC)
Colorectal cancer (CRC) is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.[1]https://en.wikipedia.org/wiki/Colorectal_cancer
Regorafenib is the first small molecule tyrosine kinase inhibitors(TKI) proven to be effective in patients with metastatic colorectal cancer (mCRC). Based on the impressive efficacy and safety data of regorafenib, current guidelines/standards consistently recommend regorafenib as the third-line standard treatment for metastatic colorectal cancer with a high level of evidence.
Regorafenib can effectively control the tumor, prolong the survival of patients, and bring survival benefits to patients with third-line and above CRC.
Gastro oesophageal junction (GOJ) cancer
The gastro oesophageal junction is where your food pipe (oesophagus) joins your stomach. Cancer that starts here is called gastro oesophageal junction (GOJ) cancer, which is one of the most common malignant tumors of the digestive system in the world.
Clinical research shows that regorafenib has shown a good effect in the treatment of GOJ cancer, especially for patients with metastatic and recurrent gastroesophageal cancer, the curative effect of regorafenib is even more exciting.
Meanwhile, the research and development process of regorafenib continues to accelerate, and has been explored in a variety of tumors. It is reported that Phase II Study of Regorafenib as Maintenance Therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy is conducted(EREMISS). [2]https://clinicaltrials.gov/ct2/show/NCT03793361
